Dainippon Of Japan Seeks Approval For First-Line Diabetes Drug
This article was originally published in PharmAsia News
Japan's Dainippon Sumitomo Pharma has applied for approval of a reformulated version of metformin, a diabetes drug. Dainippon wants to sell its SMP-862 drug in a larger dose as the primary treatment for Type 2 diabetes. Metformin itself was approved in Japan in 1961 as Melbin, but has been approved only as a second-line treatment in case other drugs fail to work. The company is relying on foreign trials rather than conducting new trials, because it licensed the drug from Merck Sante. (Click here for more - a subscription may be required
You may also be interested in...
The German pricing and reimbursement system has been successful in recognizing the value and uniqueness of orphan drugs.
Erectile problems prevent a quarter of Brits from being intimate with a partner. Viatris' Upjohn - which markets Viagra Connect in the UK - is working with the Men’s Health Forum, sexual health charity Brook and dating expert Sarah Louise Ryan raise awareness of the problem and get men talking about the issue with their partners and with healthcare professionals.
Medtechs took a long look at themselves as they rose to the challenges of COVID-19. How they responded, repurposed and regrouped to tackle the coronavirus was both sobering and uplifting. The lessons of 2020 must be integrated into the digitally-enabled health care systems of 2021 and beyond.